methyl 6-chloroimidazo[1,2-a]pyridine-3-carboxylate, 5g

(S)-3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(thiophen-3-yl)propanoic acid, 95.0%, 100mg

4-Quinazolinamine, N-(1-cyclohexyl-4-piperidinyl)-2-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-6-methoxy-7-[3-(1-piperidinyl)propoxy]-, 98%, 5mg

((4-(Bromomethyl)phenyl)sulfonyl)(4-fluorophenyl)amine, 95.0%, 500mg

5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole>98.0%(GC)1g

Methyl 6-nitro-1H-indole-2-carboxylate, 95.0%, 1g

tert-butyl rac-(3aR,4R,7aS)-octahydro-1H-isoindol-4-ylcarbamate hydrochloride, 95.0%, 1g

Ethyl 2,6-dichloro-5-methylpyridine-3-carboxylate, 97%, 250mg

Methyl 3-phenylpropionate, 98.0%, 500g

Colonna capillare per GC ROTI®Cap-5 HT, 30 m, 0.25 mm, 0.25 µm, 1 Pezzo(i)

[1,4'-Bipyridin]-1-ium chloride hydrochloride, 95.0%, 5g

(4R)-4-Isopropyl-1-methyl-7-oxabicyclo[4.1.0]heptane, 95.0%, 1g

(5-Amino-2-butylbenzofuran-3-yl)(4-(3-(dibutylamino)propoxy)phenyl)methanone, 98%, 5g